MILAN, Italy--(BUSINESS WIRE)--Flamel Technologies (NASDAQ:FLML) announced that Professor Christian Trepo presented the results of its clinical trial of Flamel’s Medusa formulation, Alpha Interferon XL (IFN-alpha XL), in an oral session at the Annual Meeting of the European Association for the Study of the Liver today. The clinical trial, in which patients were each injected over a two-week period, was designed to compare the pharmacokinetics and pharmacodynamics of IFN-alpha XL versus ViraferonPeg™ (marketed in the U.S. as PegIntron™) in patients with chronic hepatitis C virus (HCV) infection. Flamel’s product, like PegIntron, is a once-weekly injection based upon interferon alpha 2b. Flamel’s IFN-alpha XL demonstrated superior antiviral activity and a favorable safety profile as compared with PegIntron.
